Related Experiment Video
Updated: Sep 14, 2025
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the
Martin H Voss1, Howard Gurney2, Vagif Atduev3
1Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background And Objective:
Initial results from the KEYNOTE-B61 trial demonstrated that pembrolizumab combined with lenvatinib has promising antitumor activity in previously untreated advanced non-clear-cell renal cell carcinoma (nccRCC). We report updated efficacy and safety results after nearly 2 yr of follow-up.
Methods:
The single-arm, multicenter, phase 2 KEYNOTE-B61 trial enrolled patients aged ≥18 yr with previously untreated advanced nccRCC. All participants received pembrolizumab 400 mg intravenously every 6 wk (up to 18 cycles, approx. 2 yr) plus lenvatinib 20 mg orally once daily. The primary endpoint was the objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors v1.1 as assessed on blinded independent central review. Duration of response (DOR) and safety were secondary endpoints.
Key Findings And Limitations:
A total of 158 patients received at least one dose of study treatment. Median follow-up was 22.8 mo (range 16.6-27.6). The ORR was 51% (95% confidence interval 43-59); 13 patients (8.2%) had a confirmed complete response and 67 (42%) had a confirmed partial response. In the subgroup with a confirmed response, median DOR was 19.5 mo (range 1.5+ to 23.5+). ORR was generally consistent across subgroups, including histologic subtypes (34-67%) and the presence of sarcomatoid features (47%). Grade 3 or 4 treatment-related adverse events were reported for 92 patients (58%). No deaths due to treatment-related adverse events occurred.
Conclusion And Clinical Implications:
After approximately 2 yr of follow-up, pembrolizumab plus lenvatinib showed durable antitumor activity in KEYNOTE-B61, with no new safety signals. These results support pembrolizumab + lenvatinib as a first-line treatment option for advanced nccRCC.
More Related Videos
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:06Renal Drug Clearance: Overview
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...